I don’t hate Sinclair but what he did with resveratrol was pretty dodgy. Hopefully he uses that $720 million for the good of longevity is all I can say.
Do you mean Peter?
Personally i dont have expertise in biology so i cannot judge sinclairs work
I am his fan
U are entitled to ur opinions
I do have a baxkgrouns in the social sciences and have read biology papers leisurely for years
David is a professor his job is ti amplify his labs work and get funding of course
Osk seems to be very interesting to me
2 Likes
Science is hard
Reversing aging is obv goihg ti be filled with ups and downs
But i think we are really there now
At least in mouse and primates haha
Not just david lab but other labs
1 Like
We really aren’t. Nobody has mice living much longer, even the crooks can’t do it. I had high hopes for the people in Brazil trying to redo Harold Katcher’s E5. They couldn’t find rats the right age and are still waiting I think till June?
1 Like
Huh?
Osk has worked v well for mice in organs and also lifespan extension.
Ryan lu has a paper on extending mice lifespan with osk here. They basically injected very old mice with osk and did 1 week on 1 week off.
Those injected lived significantly longer (100%). Its a delivery issue, they cant get osk to every aged cell probably.
If they injected osk into middle aged mice, i guess the extension will be more in absolute terms but they cant wait for years for these mice to die so they probably chose 124 week old mice as a proof of concept of lifespan extension.
I am pretty sure these results are reproducible so we shall see if labs worldwide are able to reproduce and improve on the genes and delivery.
Itp has tested substances such as rapa asta etc that extended median lifespan of mice
I think if they can regrow cut optic nerves they probably can extend median lifespan … esp with heart diseases and cancer also progressing in treatments
Rapa has a lot of side effects i heard. David tried it but stopped. The bryan johson guy too he stopped.
Ok, yes it looks like it makes them live maybe on average 5 weeks more. Still that’s average, treated mice are dying right along. The curve goes down to zero. I look forward to future reports on this one. Interesting that it works at all.
The mice aren’t living forever yet.
Welcome, but they didn’t, it was a publicly traded company and GSK paid way over the market price. Sinclair made ~1% of it.
1 Like
Anything with David Sinclair’s name on, I will look 180 deg away… and simply ignore…
2 Likes
You are close. 1% of $720 million is, of course, $7.2million. Sinclair received $8 million from the sale, according to Securities and Exchange Commission documents. He also had earned $297,000 a year in consulting fees from the company, according to The Wall Street Journal.
2 Likes
They cant deliver the osk to every cell to rejuvenate it so it makes sense many cells are still aged
But they rejuvenated enough cells to extend lifespan of the mouse
Its really a delivery issue
And they need further proof it is safe, the aav itself and that the osk does not cause mini tumours
1 Like
Yep. My bad.
This is a good point.
Correct. GSK paid way over the top. But why? Because they were convinced it was the “Holy Grail”. And who did the sales spiel?
You see, it’s all about perception. I don’t believe DS is a bad guy, but he sung the praises of resveratrol like a nightingale until the deal was done. Then he was off to the next “hot topic”.
1 Like
This was in 2008 about 20y ago.
Well kudos to david, there is nothing wrong with a professor making money 
Haha
For me i just follow the science
I think the osk papers are real and reproducible thats the key
They are doing human trials right now as we type!
Most people fault GSK for doing poor due diligence in this case. Small companies selling their business will always present the best case scenario, thats to be expected. It’s for the buyer to do their due diligence and find out what is questionable, or identify risks, beforehand.
Most biotech companies fail, nobody knows that better than GSK. It’s part of the cost of doing business.
I suspect David Sinclair was minimally involved in this transaction, it was a spin-out company from Harvard, and the original scientists typically play a minor role in the ongoing company.
The bigger issue I think most people have with David is his ongoing promotion of Resveratrol long after people had repeatedly failed to replicate the initial studies. And the many years of post-docs lives that were wasted in already evaluated (and failed) experiments. Hype not only costs consumers the money they waste on useless supplements, but also on the PHDs and Postdocs that go down fruitless rabbit holes of false leads.
4 Likes